Angiotensin-II Receptor Antibodies Blockade With Losartan in Patients With Lupus Nephritis
Status:
Unknown status
Trial end date:
2019-10-31
Target enrollment:
Participant gender:
Summary
Antibodies directed against angiotensin-II receptor (AT1-Ab) are agonist antibodies
previously studied in human diseases such as preeclampsia, transplantation and scleroderma.
They act by binding to the AT1 receptor and their effects can be blocked with the use of
angiotensin receptor blockers (ARB). In this randomized open clinical trial the investigators
will study the effect of the blockade of AT1-Ab with losartan in carotid intima-media
thickness progression in patients with lupus nephritis compared to patients treated with
enalapril.
Phase:
N/A
Details
Lead Sponsor:
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Collaborator:
National Council of Science and Technology, Mexico